GBL Would Become A DEA Controlled Substance Under House Date Rape Bill
This article was originally published in The Tan Sheet
Executive Summary
Gamma butyrolactone (GBL) would be classified as a controlled substance under the proposed Hillary J. Farias Date-Rape Prevention Drug Act. The bill (HR 2130), introduced June 10 by Rep. Fred Upton (R-Mich.), unanimously passed the House Commerce/ Health Subcommittee at a mark-up July 27. Senate companion legislation is being drafted; the House bill is expected to go before the full Commerce Committee in the next few weeks.
You may also be interested in...
Congressional Ephedra Action Could Spring From Election Of Rep. Davis
Congresswoman-elect Susan Davis (D-Calif.) could carry her state-level efforts to enact legislation requiring warning labels on ephedra-containing dietary supplements with her into the federal arena.
GBL
Hillary J. Farias Date Rape Prevention Drug Act (HR 2130) passes the full House Commerce Committee by voice vote Aug. 5. The bill, which would classify both gamma butyrolactone and gamma hydroxybutyric acid as controlled substances, passed the Commerce/Health Subcommittee July 27 (1"The Tan Sheet" Aug. 2, p. 4). The bill should reach the House floor in the weeks following Labor Day. Sen. Spencer Abraham (R-Mich.) introduced companion legislation (S 1561) Aug. 5, which was referred to the Judiciary Committee
GBL Control Measures Due To Possible Date Rape Use Being Explored
The Drug Enforcement Administration is "reviewing various control measures of GBL" that may reduce the possibility the substance could be converted into the related compound GHB and used as a date rape drug. DEA Deputy Director Terrance Woodworth announced the possibility in comments prepared for a March 11 House Commerce/Oversight & Investigations Subcommittee hearing on date rape drugs.